2025-06-26T08:59:52-05:00 2024-12-31 042571780 AAFCPAS INC 50 WASHINGTON STREET WESTBOROUGH MA 01581 990 2024-01-01 043462719 ALS THERAPY DEVELOPMENT FOUNDATION INC ALST 6174417200 480 ARSENAL STREET 201 WATERTOWN MA 02472 DR FERNANDO VIEIRA CEO/CSO 6174417200 2025-06-25 1 1 CAITLIN LIMOGES CPA P01633588 5083669100 2025-06-25 2024 2025-03-06 01:10:19Z ALS THERAPY DEVELOPMENT INSTITUTE DR FERNANDO VIEIRA 480 ARSENAL STREET 201 WATERTOWN MA 02472 14580804 0 X WWW.ALS.NET X 1999 MA WE ARE COMMITTED TO CREATING AND LEADING A TRANSPARENT COLLABORATIVE RESEARCH PROCESS THAT INVOLVES ALS PATIENTS TODAY AND HONORS THOSE WHOSE JOURNEY WITH THIS DISEASE HAS ENDED. WE ARE GUIDED BY PASSION, LOVE AND THE SPIRIT OF ENTREPRENEURSHIP UPON WHICH WE WERE FOUNDED. 17 16 59 500 0 0 10029574 11328179 657980 1312529 363770 465979 507158 299484 11558482 13406171 0 0 0 0 4968144 5595580 27160 26875 620667 6165289 7256610 11160593 12879065 397889 527106 20012651 23052170 5001719 4418122 15010932 18634048 OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS. 0 0 11714119 1312529 ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM FOR ALS, AND IT BRIDGES A CRITICAL RESEARCH GAP. OUR IN-HOUSE EXPERTISE TRANSLATES RESEARCH INTO POTENTIAL DRUG CANDIDATES BY SCREENING DRUGS IN THE SOD1 MOUSE MODEL OF ALS. OUR SCIENTIFIC COLLABORATIONS ARE DESIGNED TO BRING THE MOST PROMISING LEADS CLOSER TO PATIENT USE. WE SHARE EMERGING KNOWLEDGE ON THE DISEASE WITH PATIENTS, PHYSICIANS, AND RESEARCHERS AS QUICKLY AND COMPREHENSIVELY AS POSSIBLE. EVERY DECISION IS MADE IN THE INTEREST OF FINDING EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH ALS. OUR UNIQUE APPROACH ACCELERATES DRUG DEVELOPMENT FOR ALS. 11714119 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 30 0 1 59 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 17 16 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX SD UT VT VA WA WV WY WI X X INSOURCE SERVICES INC 7812351490 148 LINDEN STREET WELLESLEY MA 02482 FERNANDO VIEIRA CEO AND CSO 40.00 X X 386901 0 28032 LYNNE NIETO CHAIRMAN 2.50 X X 0 0 0 STEVEN PERRIN PHD VICE CHAIR 2.50 X X 0 0 0 THEODORE REICH JD CPA TREASURER AND BOARD MEMBER 2.50 X X 0 0 0 DR STANLEY H APPEL MD BOARD MEMBER 2.50 X 0 0 0 ALEXANDER CAPPELLO BOARD MEMBER 2.50 X 0 0 0 DR SPIROS JAMAS SCD BOARD MEMBER 2.50 X 0 0 0 JAMES ALLEN HEYWOOD BOARD MEMBER 2.50 X 0 0 0 JOHN B HEYWOOD PHD SCD BOARD MEMBER 2.50 X 0 0 0 ROB RODIN BOARD MEMBER 2.50 X 0 0 0 PAUL SALLABERRY BOARD MEMBER 2.50 X 0 0 0 ROBERT SEPUCHA BOARD MEMBER 2.50 X 0 0 0 JENNY DWYER BOARD MEMBER 2.50 X 0 0 0 MIKE SMITH BOARD MEMBER 2.50 X 0 0 0 JULIE SWAN BOARD MEMBER 2.50 X 0 0 0 KENT JACKSON BRANSFORD MD BOARD MEMBER 2.50 X 0 0 0 ANDREW NIBLOCK BOARD MEMBER (LEFT IN DEC 2024) 2.50 X 0 0 0 TOM ENGELLENNER BOARD MEMBER 2.50 X 0 0 0 ALAN GILL VP OF RESEARCH 40.00 X 188954 0 19776 CAROL HAMILTON VP OF DEVELOPMENT 40.00 X 172628 0 14505 THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 40.00 X 155581 0 13972 KYLE R DENTON DIRECTOR, CELL BIOLOGY 40.00 X 158381 0 26707 MEGHAN BUCO SENIOR DIRECTOR OF MARKETING & COMMUNICATIONS 40.00 X 135001 0 20819 1197446 0 123811 10 0 1 0 INSOURCE SERVICES INC PO BOX 427 NEWTON UPPER FALLS MA 02464 FINANCE, HR & IT 573233 ALBERT EINSTEIN COLLEGE OF MEDICINE 100 WEST 33RD STREET NEW YORK NY 10001 RESEARCH CONSULTANT 137111 SOMALOGIC OPERATING CO INC 2945 WILDERNESS PL BOULDER CO 80301 RESEARCH CONSULTANT 135000 LATHROP GAGE ACCOUNTS RECEIVABLE POST OFFICE DRA COLUMBIA SC 29211 LEGAL 124101 4 5134455 682269 5511455 150209 11328179 PHARMACEUTICAL CONTRACTS 541700 1312529 1312529 1312529 465979 465979 1474117 5134455 1174633 299484 299484 13406171 1312529 0 765463 414933 331947 41493 41493 4149414 3837067 226446 85901 132524 121935 7436 3153 556596 510750 31566 14280 342113 312535 20181 9397 261399 216955 44444 37352 37352 26875 26875 421951 348702 33282 39967 48241 314 47927 228471 181954 8400 38117 678532 588964 3379 86189 1505161 1436922 57054 11185 1216 1116 100 135540 40488 95052 20118 20118 263248 246529 11495 5224 88988 81129 5302 2557 TESTING AND LAB EXPENSE 3340639 3340639 MISCELLANEOUS 130105 42512 11708 75885 PROGRAM SUPPLIES AND MA 68119 29277 1618 37224 DUES AND SUBSCRIPTIONS 23700 21905 1745 50 3830 2361 1378 91 12879065 11714119 544279 620667 282198 408496 6415329 4143356 455824 389277 97420 327321 297565 191952 3652876 2925366 393002 727510 7976815 13446822 875678 970777 3218820 2446659 20012651 23052170 426183 567204 153454 85556 4422082 3765362 5001719 4418122 X 14810932 18159048 200000 475000 15010932 18634048 20012651 23052170 527106 3096010 0 X X 0 1 X 1 0 X 8062216 10588016 9817402 10029574 11328179 49825387 8062216 10588016 9817402 10029574 11328179 49825387 49825387 17725 8195 66813 363770 465979 922482 90017 3794 103162 3581 200554 50948423 4974904 0.97800 0.97590 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 90,017. 2021 AMOUNT: $ 3,794. 2022 AMOUNT: $ 103,162. 2023 AMOUNT: $ 3,581. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 62470 50028 12442 3590406 2875338 715068 727510 RIGHT-OF-USE ASSETS - FINANCE 225700 RIGHT-OF-USE ASSETS - OPERATING 2220959 2446659 FINANCE LEASE LIABILITIES 241260 OPERATING LEASE LIABILITY 3164427 CONDITIONAL GRANT ADVANCES 359675 3765362 X 16504697 3096010 2516 3098526 13406171 0 13406171 12881581 2516 2516 12879065 0 12879065 PART X, LINE 2: ALS TDI ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH ASC TOPIC, INCOME TAXES. THIS STANDARD CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS AND PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENTS REGARDING A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. ALS TDI HAS DETERMINED THAT THERE ARE NO UNCERTAIN TAX POSITIONS WHICH QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THEIR FINANCIAL STATEMENTS AT DECEMBER 31, 2024. THE INFORMATIONAL RETURNS OF ALS TDI ARE SUBJECT TO EXAMINATION BY THE FEDERAL AND STATE JURISDICTIONS AND GENERALLY REMAIN OPEN FOR THE MOST RECENT THREE YEARS. X X X 1 REBECCA WETZEL 13 N SUMMIT AVE CHATHAM NJ 07928 HOSTING EVENTS, AND SOLICITING MAJOR DONORS, FROM HER PERSON 0 340374 26875 313499 340374 26875 313499 AZ CA FL HI IL KY MI MS MT NH NJ NM ND OK SC UT VA WV WY WA WHITE COAT AFFAIR 738200 630366 107834 8183 293753 145114 1442 80377 TRI-STATE TREK 666750 653800 12950 112651 9288 74214 325 5203622 3850289 1353333 228994 24752 4462 191403 6608572 5134455 1474117 8183 635398 179154 5904 345994 1174633 299484 X X X X 0 0 0 0 0 0 0 0 0 FERNANDO VIEIRA CEO AND CSO 386901 0 0 0 0 0 7702 0 20330 0 414933 0 0 0 ALAN GILL VP OF RESEARCH 188954 0 0 0 0 0 7514 0 12262 0 208730 0 0 0 CAROL HAMILTON VP OF DEVELOPMENT 172628 0 0 0 0 0 6959 0 7546 0 187133 0 0 0 KYLE R DENTON DIRECTOR, CELL BIOLOGY 158381 0 0 0 0 0 6377 0 20330 0 185088 0 0 0 THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 155581 0 0 0 0 0 6426 0 7546 0 169553 0 0 0 MEGHAN BUCO SENIOR DIRECTOR OF MARKETING & COMMU 135001 0 0 0 0 0 5602 0 15217 0 155820 0 0 0 CLARE REICH EMPLOYEE 8175 DAUGHTER OF A BOARD MEMBER; WAGES PAID AS AN EMPLOYEE 0 X 7 150209 FMV 0 1 0 FORM 990, PART VI, SECTION A, LINE 2 JAMES HEYWOOD, BOARD MEMBER, IS THE SON OF JOHN HEYWOOD, MEMBER OF THE BOARD OF DIRECTORS. ADDITIONALLY, LYNNE NIETO AND KENT BRANSFORD, BOARD MEMBERS, ARE RELATED. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND THEN APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ALS TDI HAS A WRITTEN CONFLICT OF INEREST POLICY WHICH REQUIRES ANNUAL SIGNOFFS BY OFFICERS, DIRECTORS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE PROCESS TO DETERMINE THE COMPENSATION OF THE PRESIDENT CONSISTS OF EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, ALONG WITH THE REVIEW AND APPROVAL BY THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS. FORM 990, PART VI, SECTION B, LINE 15B: THE PROCESS TO ESTABLISH COMPENSATION OF OTHER OFFICERS AND KEY EMPLOYEES IS COMPLETED ON AN ANNUAL BASIS BY EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, PRESENTING RECOMMENDATIONS TO THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS AND DOCUMENTING SUCH DISCUSSIONS IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 18 ALS TDI'S FORM 990 IS AVAILABLE FOR PUBLIC INSPECTION ON ALS TDI'S WEBSITE AND AT WWW.GUIDESTAR.COM. ALS TDI'S FORM 1023 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE MADE AVAILABLE ON ALS TDI'S WEBSITE AND ARE AVAILABLE BY MAIL UPON REQUEST. GOVERNING DOCUMENTS AND ALS TDI'S CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: DURING 2024, THE ORGANIZATION DID NOT CHANGE THE WAY IN WHICH ITS COMMITTEE ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT, ITS FINANCIAL STATEMENTS, AND SELECTION OF AN INDEPENDENT ACCOUNTANT.